TORONTO – Some of the most active companies traded Wednesday on the Toronto Stock Exchange and the TSX Venture Exchange:
Toronto Stock Exchange (14,533.39 down 22.58 points):
MGM Energy Corp. (TSX:MGX). Oil and gas. Unchanged at 18.5 cents on 35.7 million shares.
Bombardier Inc. (TSX:BBD.B). Aerospace. Down two cents, or 0.50 per cent, to $4.01 on 14.2 million shares.
Osisko Mining Corp. (TSX:OSK). Miner. Up 20 cents, or 2.59 per cent, to $7.93 on 8.4 million shares.
Fortis Inc. (TSX:FTS.IR). Utilities. Down 19 cents, or 0.53 per cent, to $35.70 on 6.6 million shares.
Pacific Rubiales Energy Corp. (TSX:PRE). Oil and gas. Down $1.44, or 6.66 per cent, to $20.19 on 4.8 million shares.
Yamana Gold Inc. (TSX:YRI). Miner. Up six cents, or 0.70 per cent, to $8.61 on 4 million shares.
Toronto Venture Exchange (1,010.98 up 6.10 points):
Diagnos Inc. (TSXV:ADK). Application software. Up one cent, or 15.38 per cent, to 7.5 cents on 4.8 million shares.
POET Technologies Inc. (TSXV:PTK). Semiconductors. Down 26 cents, or 10.66 per cent, to $2.18 on 4.6 million shares.
Companies reporting major news:
Celestica Inc. (TSX:CLS). Computer hardware. Up 19 cents, or 1.58 per cent, to $12.25 on 395,007 shares. The company says it had US$47.1 million of adjusted net earnings in the first quarter, or US$37.3 million under standard accounting — both up substantially from the same time last year despite soft demand for some of its manufacturing services. The adjusted earnings amounted to 26 cents per share — above the high end of Celestica’s guidance and up from 16 cents per share in the first quarter of 2013.
Mega Brands Inc. (TSX:MB). Toy manufacturer. Unchanged at $17.74 on 238,564 shares. The company shareholders overwhelmingly approved a US$460-million friendly takeover of Canada’s only public toy company by American giant Mattel. A total of 99.96 per cent of Mega Brands shareholders who voted endorsed the deal, well in excess of the two-thirds requirement.
Valeant Pharmaceuticals International Inc. (TSX:VRX). Drug manufacturers. Down $4.13, or 2.76 per cent, to $145.25 on 694,613 shares. The company says three of its directors will not stand for re-election this year as it pursues the acquisition of Botox maker Allergan. The departures come after Valeant teamed with activist investor Bill Ackman to make a hostile takeover offer for Allergan (NYSE:AGN), which has since announced it has adopted a shareholder rights plan that will allow its board time to consider alternatives and potentially block the bid.